GlycoMeds requests an EUA from the FDA for Swine Flu Medication

June 10, 2009 - PRLog -- PHOENIX –  The Swine Flu killed 50 million people in 1918 by triggering the body’s immune system to start a cytokine storm. The cytokine storm killed mainly healthy individuals between the ages of 10 and 55. While most of the dead had already gotten over the initial flu infection before they died of the double pneumonia caused by the storm.

The US Secretary of Health has declared the Swine Flu to be a national emergency and has asked the CDC to find all potential medications that could be used to combat this threat. In response to this emergency the CDC has requested the FDA to process Emergency Use Authorization (EUA) letters for medications that may have this potential.

From work done in 2001 to 2006 using frozen tissue sections from 1918 the killer cytokine storm usually started by the time the infection reached a high grade inflammatory condition. This was generally within 24 hours after infection or 17 hours after symptoms started. Once the storm starts the researchers found that there were no medications that could turn off the immune system response and stop the storm. They also found that there are no medications that will cure pneumonia that is storm induced.

There are currently only two prescription antiviral drugs that are known to mitigate the effects of the Swine Flu. These medications are Tamiflu and Relenza. As of January 2009 the virus had developed a 98% resistance to Tamiflu and, according to the FDA, neither of these two antiviral drugs will cure the flu in less than six or seven days.  

GlycoMeds has developed a broad spectrum antiviral product that kills the Swine Flu virus very quickly. Human testing has shown that one capsule can kill a whole body Influenza infection in four to 12 hours even if started several days into the infection.

Unlike all of the competing flu products on the market today that just treat symptoms GlycoMeds’ product is the only one that actually kills the virus within a few hours which is fast enough to stop the cytokine storm condition. While this product is equally effective if taken several days into the infection it will do little good to prevent the cytokine storm unless its taken when symptoms begin.

GlycoMeds’ CEO, Dr. Roger Brown, said they requested an EUA from the FDA on May 20, 2009 and are waiting for the FDA to complete a non-disclosure agreement to protect their patent pending invention. Their product was also submitted to NIAID in March for antiviral evaluation against a number of virus.

GlycoMeds has packaged their system so it can be sold as an over the counter (OTC) medication not requiring a prescription. They are looking for a company to license and market their new product line.

More information about their discovery is available on GlycoMeds' web site at: http://www.glyco-meds.com/coldBoosterPlusFormula.html

Contact:

Roger Brown, Ph.D.
GlycoMeds
602-441-4225
g-cust-serv@glyco-meds.com
http://www.glyco-meds.com/contactUs.html

# # #

GlycoMeds started doing antiviral research in Phoenix Arizona in 2005. We currently have a dozen products covering the areas of: antiviral, pain and hypertension. We have filed patent applications covering these products. We are expanding our research.